Our previous studies showed that macrophages (MФs), especially myeloma-associated MФs (MAMs), induce chemoresistance in human myeloma. Here we explored the potential of targeting MФs, by using colony-stimulating factor 1 receptor (CSF1R)-blocking mAbs, to treat myeloma. Our results showed that CSF1R blockade specifically inhibited the differentiation, proliferation and survival of murine M2 MФs and MAMs, and repolarized MAMs towards M1-like MФs in vitro. CSF1R blockade alone inhibited myeloma growth in vivo, by partially depleting MAMs, polarizing MAMs to the M1 phenotype, and inducing a tumor-specific cytotoxic CD4 + T-cell response. Similarly, genetically depleting MФs in myeloma-bearing MM DTR mice retarded myeloma growth in vivo. Furthermore, the combination of CSF1R blockade and chemotherapy such as bortezomib or melphalan displayed an additive therapeutic efficacy against established myeloma. Finally, a fully human CSF1R blocking mAb, similar to its murine counterpart, was able to inhibit the differentiation, proliferation and survival of human MФs. Thus, this study provides the first direct in vivo evidence that MΦs and MAMs are indeed important for myeloma development and progression. Our results also suggest that targeting MAMs by CSF1R blocking mAbs may be promising methods to (re)sensitize myeloma cells to chemotherapy and promote antimyeloma immune responses in patients.
INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow (BM) and destructive lytic bone disease. 1, 2 In recent years, chemotherapy combined with novel agents, such as lenalidomide and bortezomib, has greatly improved the therapeutic efficacy for patients with MM; however, MM still remains largely incurable. Therefore, investigation of novel strategies for MM therapy has important clinical significance.
Macrophages (MΦs) are heterogeneous cell populations originating from blood monocytes. 3 In general, MΦs can be divided into two major phenotypes, M1 and M2. M1 MΦs are polarized under inflammatory conditions and have a central role in fighting pathogen infections, whereas M2 MΦs are associated with antiinflammatory responses. [4] [5] [6] Tumor-associated MΦs are an important component of cancers. M1-like tumor-associated MΦs suppress cancer progression, whereas M2-like tumor-associated MΦs promote tumor growth. 7, 8 In the tumor microenvironment, MΦs are often educated to develop into M2-like tumor-associated MΦs by tumor-derived cytokines, such as interleukin-10 (IL-10), IL-6 and transforming growth factor-β (TGF-β). 9, 10 We previously found that MΦs accumulate in the MM BM microenvironment and protect MM cells from chemotherapy drug-induced apoptosis in vitro. 11, 12 However, the role of MΦs in MM development and progression in vivo is not fully defined.
Colony-stimulating factor 1 receptor (CSF1R) is mainly expressed by monocytes, MΦs and monocyte-like myeloid-derived suppressor cells. 13, 14 The CSF1/CSF1R axis is important in the regulation of recruitment, differentiation and functions of tissue MΦs. 15 The CSF1/CSF1R axis also has a role in educating MΦs to become M2 MΦs. 16, 17 Recent studies have shown that CSF1R blockade by inhibitors and antibodies improves therapeutic efficacy in multiple cancers, such as glioma, pancreatic cancer and diffuse-type giant cell tumor. 14, 18, 19 Based on these findings, we hypothesized that CSF1R blockade could be an important novel approach to improving MM therapy. Here, we investigated the role of MΦs in MM growth in vivo and the effect of targeting MΦs by CSF1R blocking antibodies in MM therapy.
MATERIALS AND METHODS

Rag
− / − C57BL/6 mice, OT-I (C57BL/6-Tg(TcraTcrb)1100Mjb/J), OT-II (C57BL/ 6-Tg(TcraTcrb)425Cbn/J) and Lysm Cre X Csf1r LsL -DTR C57BL/6 mice (MM RESULTS Blocking CSF1R inhibits the differentiation, survival and proliferation of murine MΦs and myeloma-associated MФs in vitro myeloma-associated MФs (MAMs) are mainly derived from peripheral blood monocytes 20 and therefore, blocking monocyte differentiation into MΦs may inhibit MΦ infiltration into MM BM. To test this hypothesis, we used an mAb (CS7) against murine CSF1R that is expressed by both murine monocytes and MΦs (Supplementary Figure 1a) . Addition of CS7 to monocyte cultures reduced their differentiation to MΦs and induced cell death in a dose-dependent manner (Figure 1a and Supplementary  Figures 1b and c) . Western blots showed that CS7 treatment downregulated the expression of phosphorylated (p)CSF1R, pERK, pAKT and mTOR, and cleaved caspases 7 and 8, and upregulated the expression of cleaved caspase 3 and cytochrome C in the cells (Supplementary Figure 1d) .
Next we examined the effect of CS7 on MAMs. Freshly differentiated normal MΦs were cocultured with 5TGM1 MM cells (to generate MAMs) in the presence of CS7 or control immunoglobulin G (IgG). CS7 but not control IgG treatment inhibited the proliferation of MAMs (Supplementary Figures 1e and f) . We also determined the effect of CS7 on in vitro polarized M1 or M2 MΦs. CS7 treatment significantly and specifically reduced the viability ( Figure 1b ) and increased apoptosis (Supplementary Figure 1g) of IL-10-or IL-4-polarized M2 MΦs [21] [22] [23] and MAMs, but had minimal effect on granulocyte-macrophage colony-stimulating factor (GM-CSF)-or lipopolysaccharides (LPS) plus interferon (IFN)-γ-polarized M1 MΦs. 24, 25 Interestingly, CS7 treatment significantly downregulated the expression of pAkt and pERK in M2 MΦs and MAMs but not in M1 MΦs (Figure 1c) . Thus, these results demonstrated that blocking CSF1R selectively inhibits the development and survival of M2 MΦs and MAMs.
Blocking CSF1R polarizes murine MAMs into M1-like MΦs in vitro
Because the above studies showed that CS7 at high doses selectively killed MAMs and M2 MΦs, we wanted to determine whether lower and non-apoptotic doses of CS7 could affect the polarization of MAMs in vitro. We cultured BM-derived MΦs with 5TGM1 cells in the presence of CS7 or control IgG (0. Figure 2a) . To more accurately assess the effect of CS7 mAb on MAM repolarization, we performed ingenuity pathway analysis to identify canonical signaling pathway activation in the cells. CS7-treated MAMs displayed activated signaling pathways of triggering receptor expressed on myeloid cells 1, GM-CSF, LPS-stimulated mitogen-activated protein kinase, and production of nitric oxide and iNOS (Figure 2b ) that are highly related to M1 MΦ polarization and function. 24, [33] [34] [35] CS7-treated MAMs also displayed activated pathways of interferon, macropinocytosis, JAK1, JAK2 and TYK2 (Figure 2b ), which are also M1 MΦ-specific gene clusters. 36 Quantitative real-time PCR showed that 5TGM1-cocultured MΦs (MAMs) expressed greater mRNA levels of M2 MΦ-associated Irf4, Arg1 and Il10 and lower levels of M1 MΦ-associated Il12a and Tnfα than untreated MΦs, whereas Irf4 and Il10 mRNA levels were decreased and Tnfa and Nos2 levels were elevated in CS7-treated MAMs (Figure 2c ). Moreover, CS7 treatment significantly downregulated the expression of CD206 in MAMs ( Supplementary  Figures 2b and c) , which is a surface marker for M2 MΦs. 26 Taken together, these results demonstrated that blocking CSF1R repolarizes M2-type MAMs to M1-like MΦs in vitro.
Blocking CSF1R inhibits tumor growth in murine MM models We reported that MΦs, especially MAMs, protected MM cells from drug-induced apoptosis. 12 To test our hypothesis that depleting MΦs and MAMs in vivo could sensitize MM cells to chemotherapy, we determined the effect of CS7 on MM growth in vivo using 5TGM1-bearing KAL mice (Supplementary Figure 3a) . Treatment with CS7 but not control IgG significantly inhibited tumor growth, as detected by bioluminescent imaging (Figure 3a As monocytes and MΦs in MM DTR mice can be almost completely depleted in vivo by diphtheria toxin injection, 37 we used the MM DTR mouse model to confirm the role of MΦs in MM development and progression. As shown in Figure 3c , ablation of monocytes and F4/80 + MΦs in MM DTR mice by diphtheria toxin treatment significantly reduced tumor burden detected at the level of circulating mouse IgG2b. These results provide the first direct evidence that MΦs play an important role in MM growth and progression in vivo, and suggest targeting these cells by CSF1R inhibitors may be therapeutic in human MM. Figure 4e) , confirming that blocking CSF1R efficiently depletes MΦs and MAMs in vivo.
We then explored the role of CSF1R blockade in MΦ polarization in vivo by examining the percentage and cytokine profile of (CD206 + ) MΦs in CS7-treated MM-bearing mice. The results showed that mice treated with CS7 had fewer CD206 + MΦs in spleen than those treated with control IgG (Supplementary Figure 4f) . In addition, although CS7 treatment did not significantly change the percentage of CD206 + MΦs in the BM, MΦs/MAMs isolated from BM of CS7-treated MM-bearing mice expressed significantly lower levels of Il10 and higher levels of Il12a and Tnfa than those from control IgG-treated MM-bearing mice (Figure 4c ). These results indicate that CSF1R blockade skews MAM phenotype to M1-like MΦs in vivo.
We also determined whether blocking CSF1R affected the development of myeloid-derived suppressor cells in vivo. As compared to control IgG, CS7 treatment had only minor effects on myeloid-derived suppressor cells (Supplementary Figure 4g) , indicating that CSF1R-blocking mAb does not deplete myeloidderived suppressor cells in vivo. Taken together, these results demonstrate that blocking CSF1R induces an anti-MM microenvironment by partially depleting MΦs and MAMs and polarizing MAMs to M1-like MΦs in vivo. The anti-MM effects of CSF1R blockade rely on tumor-specific CD4 + T-cell responses
To determine whether the immune system was required for the observed CS7-induced anti-MM effect in vivo, immunodeficient Rag − / − mice were used to establish MM (5TGM1 cells), followed by injection of CS7 or control IgG. MM growth and tumor cell infiltration of BM and spleen were similar between mice treated with CS7 or IgG control (Figure 5a and Supplementary Figures 5a  and b) , indicating that the immune system or, specifically, lymphocytes were required for CS7 mAb-induced antitumor effect in vivo.
To determine the role of T cells in the antitumor effects induced by CSF1R blockade, 5TGM1-bearing immunocompetent KAL mice were again used. Although the total number of CD4 + or CD8 + T cells infiltrating BM and lymph nodes (LNs) did not differ between MM-bearing mice treated with CS7 or control IgG (Supplementary Figure 5c) , the percentage and number of granzyme-B-expressing CD4 + and CD8 + T cells in BM and LNs were significantly higher in mice treated with CS7 ( Supplementary  Figures 5d and e) . Similarly, diphtheria toxin-treated MM-bearing MM DTR mice had higher percentages of granzyme-B-expressing CD4 + and CD8 + T cells in the BM and LNs than phosphatebuffered saline-treated mice ( Supplementary Figures 5f and g ). revealed an increased number of granzyme-B-secreting CD4 + , but not CD8 + , T cells after ex vivo restimulation with mature BMderived dendritic cells pulsed with irradiated 5TGM1, in the spleens and LNs of MM-bearing mice treated with CS7 compared to mice treated with control IgG (Figure 5c and Supplementary  Figure 5i) . These results indicate that CS7 treatment induces or enhances a tumor (5TGM1)-specific CD4 + T-cell response that may have contributed to the observed anti-MM effects in vivo. The combination of CSF-1R blockade and chemotherapy displays an additive therapeutic efficacy against MM in vivo We reported that MΦs conferred MM cell chemoresistance. 12 However, we had not determined whether CSF1R blockade could improve the chemotherapeutic efficacy in vivo. To address this issue, the protease inhibitor bortezomib, CS7, and their combination were used to treat 5TGM1-bearing KAL mice. Although mice treated with bortezomib or CS7 alone exhibited smaller tumor burden and longer survival than control IgG-treated mice, the combination of bortezomib and CS7 significantly reduced tumor burden and improved mouse survival as compared with single agent-treated mice (Figure 7a) . Similarly, 5TGM1-bearing KAL mice treated with another MM chemotherapeutic drug, melphalan, or CS7 alone exhibited smaller tumor burden and longer survival than mice treated with control IgG (Figure 7b) . Moreover, the combination of melphalan and CS7 also significantly reduced tumor burden compared with melphalan therapy alone and improved mouse survival. These results demonstrated that CSF1R blocking mAbs can be used to treat MM, especially in combination with chemotherapy.
CS7-treated
Blocking CSF1R inhibits differentiation, survival and proliferation of human MΦs in vitro Finally, to determine whether our findings can be translated into clinic, we examined the effects of a fully human mAb (CS4) that blocks human CSF1R on human monocytes and MΦs. Similar to its murine counterpart, CS4 was also able to retard monocyte differentiation to MΦs and induced cell death in a dosedependent manner (Figure 8a Figure 7g) . Taken together, these results demonstrate that blocking CSF1R signaling inhibits human monocyte differentiation into MM-supporting MΦs without affecting DCs or MM cells.
DISCUSSION
We previously reported that CD68 + MΦs heavily infiltrate the BM of patients with MM. 11 However, the role of MΦs in MM we found that CSF1R-blocking mAbs inhibited MM growth in vivo, and the combination of CSF1R-blocking mAbs and chemotherapy further improved the therapeutic efficacy against established MM. Thus, this study provides the first direct evidence that MΦs and MAMs are important for MM development and progression, and suggests that targeting MΦs will be important for improving the efficacy of chemotherapy in MM.
Tumor-associated MΦs mediate immunosuppression in many cancer types, including MM. 5,9,14 Thus, we speculated that the anti-MM effects induced by CSF1R blockade might be through ablation of MAMs, and subsequent activation of anti-MM immunity in vivo. Indeed, in this study, we found that CSF1R blockade failed to inhibit MM growth in immunodeficient mice, which lack B-and T cells. In addition, depletion of CD4 + but not CD8 + T cells abolished the anti-MM effects induced by CSF1R blockade. Notably, CSF1R blockade increased the number of cytotoxic CD4
+ (granzyme-B-producing CD4 + ) T cells in both BM and LNs. Our results are consistent with previous investigations showing that circulating CD4 + T-cell numbers decrease in MM and its precursor disease MGUS, 41, 42 and the ratio of CD4 + to CD8 + T cells was negatively related to tumor burden and MM progression. 43 Thus, our data established the important role of cytotoxic CD4 + T cells in mediating the anti-MM activity induced by CSF1R blockade.
Of interest is our finding that cytotoxic CD4 + T cells are critical for the eradication of MM during CSF1R blockade treatment, but most MM cells express a low level of MHC class II antigens on their surface. 44 Therefore, whether and how cytotoxic CD4 + T cells recognize MHC class II low MM cells remains unclear. Tveita et al. 45 addressed the question whether MHC II-deficient MM cells could be eradicated by tumor-specific CD4 + T cells and demonstrated that CD4 + T cells specific for MM antigens could eliminate MM cells in the absence of endogenous MHC II expression on the tumor cells through antigen uptake and indirect presentation on tumor-infiltrating MΦs. Our data showed that CSF1R blockade enhanced MHC II antigen presentation of MAMs, which stimulated cytotoxic CD4 + T-cell proliferation and cytolytic function in vitro. Thus, these findings provide a plausible explanation as to why CD4 + T cells are crucial for CSF1R-mediated anti-MM immune responses in vivo.
In conclusion, our study provides the first direct in vivo evidence that MΦs and MAMs are indeed important for myeloma development and progression and may have important clinical implications for the treatment of MM by targeting its microenvironment components.
